SCM
VKTX icon

Semanteon Capital Management’s Viking Therapeutics VKTX Stock Holding History

Semanteon Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,646
Closed -$203K – 238
2025
Q2 		$203K Buy
+7,646
New +$201K 0.31% 94

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Semanteon Capital Management's VKTX Position: Q3 2025 in Review

Semanteon Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 7,646 shares — an estimated $203K sold.

Semanteon Capital Management first reported a position in VKTX in Q2 2025 and held it in 1 quarter. The position peaked at $203K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Semanteon Capital Management reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Semanteon Capital Management sold 7,646 Viking Therapeutics shares in Q3 2025, an estimated $203K.
  • Semanteon Capital Management first reported a position in Viking Therapeutics in Q2 2025 and held it in 1 quarter.
  • Semanteon Capital Management's Viking Therapeutics position peaked at $203K in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Semanteon Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.